Document Detail


Inhibition of human immunodeficiency virus type 1 replication by 7-methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine, an in vivo metabolite of oltipraz.
MedLine Citation:
PMID:  7542738     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication in vitro (ED50 approximately 10 microM), undergoes extensive metabolism in vivo. Most of the orally administered drug undergoes opening of the dithiolethione ring, reduction, recyclization, and methylation to form 7-methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine ("metabolite III"). We report here that metabolite III inhibits viral replication in vitro (ED50 approximately 25 microM) in acutely infected H9 and CEM T cell lymphoma cell lines. Although both metabolite III and oltipraz were able to inhibit phorbol-12-myristate-13-acetate-stimulated viral replication in the chronically infected U1 promonocytic leukemia cell line, only metabolite III was able to inhibit phorbol-12-myristate-13-acetate-stimulated viral replication in chronically infected ACH-2 T cell lymphoma cells. The results with ACH-2 cells suggest that oltipraz inhibits an early stage of the viral life cycle, whereas metabolite III affects human immunodeficiency virus type 1 replication at a step distal to viral integration. This is consistent with the finding that oltipraz inhibits reverse transcriptase, whereas metabolite III does not. Although the mean ED50 for metabolite III in acutely infected peripheral blood mononuclear cells was 18 microM, the ED50 was below 5 microM in three of eight independent experiments. Studies of metabolite III in combination with oltipraz in acutely infected peripheral blood mononuclear cells demonstrated significant antiviral synergy. These results raise the possibility that the in vitro potency of oltipraz may underestimate its antiretroviral activity in vivo. Based on these results, the pharmacokinetics of oltipraz and metabolite III will be compared with the pharmacodynamic effects of orally administered oltipraz in a forthcoming phase I/II trial of oltipraz in patients with p24 antigenemia.
Authors:
H J Prochaska; W G Bornmann; P Baron; B Polsky
Related Documents :
9521258 - Diagnosis of cytomegalovirus encephalitis in patients with aids by quantitation of cyto...
18160118 - Species-specific deletion of the viral attachment glycoprotein of avian metapneumovirus.
1856788 - Transepithelial transport of hiv-1 by intestinal m cells: a mechanism for transmission ...
20397068 - Rotavirus cell entry.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Molecular pharmacology     Volume:  48     ISSN:  0026-895X     ISO Abbreviation:  Mol. Pharmacol.     Publication Date:  1995 Jul 
Date Detail:
Created Date:  1995-08-30     Completed Date:  1995-08-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0035623     Medline TA:  Mol Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  15-20     Citation Subset:  IM; X    
Affiliation:
Molecular Pharmacology and Therapeutics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiviral Agents / pharmacology*
Cell Line
HIV Reverse Transcriptase
HIV-1 / drug effects*,  enzymology,  physiology
Humans
Pyrazines / metabolism*,  pharmacology*
Reverse Transcriptase Inhibitors
Tumor Cells, Cultured
Virus Replication / drug effects*
Grant Support
ID/Acronym/Agency:
NCI-P30-CA08748/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Pyrazines; 0/Reverse Transcriptase Inhibitors; 64224-21-1/oltipraz; 84201-40-1/7-methyl-6,8-bis(methylthio)pyrrolo(1,2-a)pyrazine; EC 2.7.7.49/HIV Reverse Transcriptase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Implications of the use of neonatal birth weight, growth, viability, and survival data for predictin...
Next Document:  WIN 17317-3: novel nonpeptide antagonist of voltage-activated K+ channels in human T lymphocytes.